Krabbe Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Krabbe Disease (KD) is a neurodegenerative disorder inherited in an autosomal recessive pattern, stemming from a deficiency in the lysosomal enzyme galactocerebrosidase. The responsible gene, GALC, is located on chromosome 14q31.3. Typical symptoms of the "early infantile" or "early onset" form of KD include feeding difficulties, hyperirritability, periodic fever of unknown origin, psychomotor regression, and convulsive seizures. The ophthalmological examination may reveal macular cherry red spots. As the disease progresses, patients enter a stage known as "burnout," characterized by blindness, muscle weakness, and loss of voluntary movements, with some experiencing microcephaly or macrocephaly depending on disease progression. Manifestations occur at various ages: 10% of cases present between 7–12 months, 22% between 13 months and 10 years, and 5% manifest in adolescence or adulthood. KD is categorized into four clinical subtypes based on the age of onset.
Thelansis’s
“Krabbe Disease (KD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Krabbe
Disease (KD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Krabbe Disease (KD)
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Krabbe
Disease (KD) Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Krabbe
Disease (KD), Krabbe Disease (KD) market outlook, Krabbe
Disease (KD) competitive landscape, Krabbe
Disease (KD) market forecast, Thelansis, Primary
market research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment